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Abstract 13 
Human papillomavirus (HPV) vaccines are currently utilised globally in national 14 
immunisation programmes. In July 2017, a national HPV vaccine programme for men who 15 
have sex with men (MSM) was initiated across Scotland with vaccine being offered in the 16 
sexual health clinic setting. During the first year of this targeted vaccination programme, 17 
there were 5,905 individuals who received at least one dose of HPV vaccine, representing 18 
63.7% of eligible MSM attendees in this period. Vaccine uptake was relatively stable across 19 
all age groups (range 49.8-55.5%). The vaccination programme appears to have dovetailed 20 
well with pre-existing sexual health services and appears to be popular with MSM attending 21 
the service. The MSM HPV vaccine programme is a robust adjunct to the national girls 22 
programme but gender-neutral immunisation will reduce stigma and inequality in HPV-23 
driven disease.    24 
Introduction 25 
Since 2008, school-based uptake in Scotland of the HPV vaccines in girls aged 12–13 has 26 
been impressive, with vaccine uptake sustained at levels approximating 90% (Sinka et al. 27 
2014). We have recently reported on the effect of the bivalent vaccine on the prevalence of 28 
HPV types in women immunised routinely at age 12 or 13 years who attended for screening 29 
at age 20, where virtual abolition of HPV 16 and 18 infections was observed (Kavanagh et al. 30 
2017). Indeed, the prevalence of virus (0.5%) was comparable in vaccinated and 31 
unvaccinated women, demonstrating significant herd protection against the two most 32 
prevalent oncogenic HPV types known to precipitate anogenital and oropharyngeal cancers 33 
(Lin et al. 2017; Chaturvedi et al. 2013). 34 
A HPV vaccination programme for men who have sex with men (MSM) aged up to and 35 
including 45 years old who attend sexual health and/or HIV clinics commenced in Scotland 36 
in July 2017 (CMO Directorate, 2017). The vaccine is administered irrespective of HPV 37 
infection status. The programme was initiated by the Scottish Government based on advice 38 
from the UK Joint Committee on Vaccination and Immunisation (JCVI, 2015), which 39 
recognised that MSM receive little benefit from the national schools’ HPV programme in 40 
girls. Furthermore, HPV anogenital infection and related disease is disproportionately higher 41 
in MSM who are significantly more likely than heterosexual men to develop anal cancer 42 
(Piketty et al.. 2012).  43 
We present national vaccine uptake data for the first year of this selective immunisation 44 
programme for MSM attending sexual health clinics in Scotland. 45 
  46 
Methods 47 
The National Sexual Health IT System (NaSH) is currently used by all eleven mainland 48 
Scottish NHS board sexual health services (SHS) to record patient attendances. Denominator 49 
numbers of MSM were identified as those who attended 81 sexual health services during the 50 
first full year of the MSM HPV immunisation programme (1
st
 July 2017 to 30
th
 June 2018), 51 
who were age ≤ 45 years at the time of attendance, and where the patient sex was male and 52 
gender of lifetime sexual partners was recorded as "men and woman" or "men only". 53 
Immunisation status of these ‘eligible MSM’ was derived from prescription data on NaSH 54 
during the same 12 month period, with three prescriptions (or doses) of Gardasil considered 55 
'Complete' for adults and 2 doses for those under 15 years of age. Due to the flexibility in the 56 
Gardasil summary of product characteristics (SPC), variable spacing options for the doses are 57 
possible. This enables the administration of subsequent doses to be aligned with 58 
recommended GUM re-attendance, routine investigations for HIV+ MSM, or other care.  59 
Age of those vaccinated was based on the age at first prescription (i.e. when the patient first 60 
started the HPV programme) and NHS board was based on the most recent appointment 61 
location. Patients had to have a valid sexual health clinic appointment linked to their 62 
prescription. This was required to consistently identify age and NHS board. Non-linking 63 
records were excluded (43, 0.7%). Data were extracted in October 2018.   64 
         65 
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   69 
Results 70 
During the first year of this targeted opportunistic vaccination programme, there were 5,905 71 
individuals who received at least one dose of HPV vaccine. This represents a percentage first 72 
dose uptake of 63.7% of eligible MSM attendees in this period (table 1). Vaccine uptake was 73 
relatively stable across all age groups (range 49.8-55.5%). Few (447 of 5905, 7.6%) were 74 
aged under 20. In this time period, 3,367 MSM who attended sexual health services (36.3%) 75 
were eligible for HPV vaccination by age and lifetime sexual history but did not begin the 76 
programme. 77 
Table 1. Uptake of HPV vaccine in MSM within Scotland by age group (patient 78 
immunisation status was based on their most recent Gardasil prescription prescribed as 79 






















54 393 447 
 
7.6 55.5 63.1 
20-24 2,443 
 
242 1,330 1,572 
 
9.9 54.4 64.3 
25-29 2,403 
 
297 1,221 1,518 
 
12.4 50.8 63.2 
30-34 1,597 
 
223 801 1,024 
 
14.0 50.2 64.1 
35-39 1,163 
 
161 579 740 
 
13.8 49.8 63.6 
40-45 958 
 
117 487 604 
 
12.2 50.8 63.0 
Total 9,272 
 
1,094 4,811 5,905 
 
11.8 51.9 63.7 
 81 
  82 
Discussion 83 
The implementation and roll-out of the HPV vaccination programme in MSM within 84 
Scotland has been successful with a moderately high first dose uptake. The vaccination 85 
programme, designed to be opportunistic, has been accommodated into pre-existing sexual 86 
health services and is popular with MSM attending the service. Furthermore, the 1
st
 dose 87 
uptake of 64% correlates well with estimates used in cost-effectiveness models (Lin et al, 88 
2017). The HPV programme commenced simultaneously with the offer of pre-exposure 89 
prophylaxis (PrEP) to eligible HIV-negative individuals, which presented significant 90 
logistical challenges for those delivering sexual health services. Limitations of this analysis 91 
include the fact that NaSH is not currently used by the three Scottish Island Boards (Orkney, 92 
Shetland & Western Isles), and not by some mainland HIV Services. Work is ongoing with 93 
these services to determine numbers of those eligible for the HPV vaccine among the HIV 94 
cohort and those vaccinated in non-NaSH using sexual health sites and in the prison setting, 95 
though numbers are predicted to be small. 96 
The first dose uptake of 64% in Scotland broadly compares with other devolved UK nations 97 
where first dose uptake has been estimated to be 77% in specific areas of Wales (Knapper et 98 
al. 2018), 65% in Northern Ireland (HSCNI PHA, 2017) and 46% in England, albeit the latter 99 
figure was estimated through a pilot evaluation rather than national roll-out (PHE, 2018). 100 
While the offer of vaccine through sexual health clinics appears to be well-received, 101 
approximately 36% of eligible MSM attending sexual health clinics that are eligible for the 102 
vaccine have not commenced it and these men presumably remain at risk of acquiring new 103 
HPV infections. Given that 50% of MSM in Scotland are infected with a vaccine-specific 104 
HPV, the importance of increased vaccine uptake in this at-risk population cannot be 105 
understated (Cameron et al. 2018). Future analyses will detail the clinical impact of the 106 
programme in both the short and longer term.  107 
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